Status:
COMPLETED
rTMS for MDD: 5.5cm Rule vs. F3 Targeting
Lead Sponsor:
Nicholas Trapp
Conditions:
Major Depressive Disorder
Depression
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
The purpose of this study is to examine the effects of different treatment locations using repetitive transcranial magnetic stimulation (rTMS) to treat major depressive disorder.
Detailed Description
Currently there is little standardization between rTMS treatment programs as to what is the best way to localize the left dorsolateral prefrontal cortex, which is the FDA-approved treatment location f...
Eligibility Criteria
Inclusion
- Diagnosis of major depressive disorder
- Age between 18 and 90 years
- rTMS is clinically indicated as determined by clinical rTMS physician team at University of Iowa
Exclusion
- rTMS contraindication such as implanted ferromagnetic material in the head or history of epilepsy with poorly controlled seizures
- MRI exclusion criteria (if participating in MRI portion of study) including implanted device such as:
- Pacemaker
- Coronary Stent
- Defibrillator
- Neurostimulation
- Or any of the following conditions:
- Claustrophobia
- Uncontrolled high blood pressure
- Poorly controlled atrial fibrillation
- Significant heart disease
- Hemodynamic instability
- Severe kidney disease
- Pregnant, trying to become pregnant, or breast feeding
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 13 2022
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT03378570
Start Date
May 1 2018
End Date
September 13 2022
Last Update
February 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Iowa Hospitals & Clinics
Iowa City, Iowa, United States, 52242